
open access
메뉴
E-ISSN : 2671-6771
Lipoproteins and apolipoproteins are essential macromolecules that maintain systemic lipid homeostasis and cellular energy balance by transporting lipids through plasma and interstitial fluids. Structurally, lipoproteins consist of hydrophobic lipid cores surrounded by amphipathic apolipoproteins, which determine their metabolic fate, receptor interactions, and physiological functions. Among apolipoproteins, apolipoprotein E (APOE) plays critical roles in lipid transport, nerve repair, and immune regulation. APOE encoded by APOE gene (OMIM*107741) exists in three common isoforms (APOE2, APOE3, and APOE4), which differ by cysteine/arginine substitutions at residues 112 and 158. These subtle structural changes profoundly alter receptor binding affinity, lipidation efficiency, and protein stability, resulting in distinct metabolic and pathological outcomes. In particular, APOE4 is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). APOE4 promotes amyloid-β (Aβ) aggregation, impairs Aβ clearance, enhances tau hyperphosphorylation, and triggers neuroinflammatory signaling. APOE-mimetic peptides, designed to replicate key functional domains of the native protein, exhibit neuroprotective, anti-inflammatory, and lipid-modulatory effects in preclinical models of AD, stroke, and atherosclerosis. Concurrently, advances in APOE genotyping are expanding clinical applications in AD risk prediction, lipid-lowering therapy, and personalized prevention. Understanding the molecular mechanisms and clinical relevance of the APOE gene remains essential for translating genetic insights into therapeutic and diagnostic innovation across metabolic and neurodegenerative diseases. This review highlights the APOE gene as a pivotal link between lipid metabolism and neurodegeneration. Integration of recent advances in its structural variants, disease mechanisms, therapeutic modulation, and clinical genotyping underscores the importance of APOE as both a biomarker and a therapeutic target.